Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Jun;36(3):131-49.
doi: 10.1046/j.1365-2184.2003.00266.x.

The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer

Katrien Vermeulen  1 , Dirk R Van Bockstaele, Zwi N Berneman
Affiliations
Review

The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer

Katrien Vermeulen et al. Cell Prolif. 2003 Jun.

Abstract

The cell cycle is controlled by numerous mechanisms ensuring correct cell division. This review will focus on these mechanisms, i.e. regulation of cyclin-dependent kinases (CDK) by cyclins, CDK inhibitors and phosphorylating events. The quality checkpoints activated after DNA damage are also discussed. The complexity of the regulation of the cell cycle is also reflected in the different alterations leading to aberrant cell proliferation and development of cancer. Consequently, targeting the cell cycle in general and CDK in particular presents unique opportunities for drug discovery. This review provides an overview of deregulation of the cell cycle in cancer. Different families of known CDK inhibitors acting by ATP competition are also discussed. Currently, at least three compounds with CDK inhibitory activity (flavopiridol, UCN-01, roscovitine) have entered clinical trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The stages of the cell cycle. The site of activity of regulatory CDK/cyclin complexes is also indicated.
Figure 2
Figure 2
A schematic overwiew of some essential steps in cell cycle regulation. formula image, phosphorylated site. (→: activation; formula image: inhibition)
See this image and copyright information in PMC

References

    1. Abraham RT, Acquarone M, Andersen A, Asensi A, Belle R, Berger F, Bergounioux C, Brunn G, Buquet FC, Fagot D, Glab N, Goudeau H, Goudeau M, Guerrier P, Houghton P, Hendriks H, Kloareg B, Lippai M, Marie D, Maro B, Meijer L, Mester J, Mulner‐Lorillon O, Poulet S, Schierenberg E, Schutte B, Vaulot D, Verlhac M (1995) Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases. Biol. Cell 83, 105. - PubMed
    1. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The p53 network. J. Biol. Chem. 273, 1. - PubMed
    1. Amon A (1999) The spindle checkpoint. Curr. Opin. Genet. Dev. 9, 69. - PubMed
    1. Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Giorgi G, Salvini L, Garaliene V (2001) Synthesis and antitumor activity of substituted 3‐(5‐imidazo[2,1‐b]thiazolylmethylene)‐2‐indolinones. Anticancer Drug Des. 16, 167. - PubMed
    1. Arellano M, Moreno S (1997) Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol. 29, 559. - PubMed

MeSH terms

LinkOut - more resources